TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02881814

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung and diaphragm ultrasound
Description: The ultrasound physiotherapist/operator performs a lung and diaphragm ultrasound. He is blinded to the patient's status and clinical physiotherapist examination. He/she is not involved in patient management or patient clinical decision-making. The ultrasound findings are recorded in the LUS report. The LUS report is reported to the clinical physiotherapist and to the intensivist. The ultrasound diagnosis(es) is recorded.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung and diaphragm ultrasound
Description: The ultrasound physiotherapist/operator performs a lung and diaphragm ultrasound. He is blinded to the patient's status and clinical physiotherapist examination. He/she is not involved in patient management or patient clinical decision-making. The ultrasound findings are recorded in the LUS report. The LUS report is reported to the clinical physiotherapist and to the intensivist. The ultrasound diagnosis(es) is recorded.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Lung and diaphragm ultrasound in MV patients
Description: In case of mechanically ventilated patient at St. Vincent Hospital (Sydney, Australia), LUS scan will be performed immediately following intubation. Additionnal LUS scans will be performed 72h after intubation and Immediately prior to or following extubation.
Study: NCT01835249

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive BP Arm
Description: Participants in the Intensive arm have a goal of SBP \<120 mmHg.
Study: NCT01042379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) + Carboplatin with or without trastuzumab
Description: For HER2+ Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Trastuzumab, 4 mg/kg cycle 1, then 2 mg/kg cycles 2-12 q1wk, IV, for wk1-12 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Carboplatin, AUC 1.5, IV, q1wk from wk1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle~For HER2- Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Carboplatin, AUC 1.5, IV, q1wk from wk1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle
Study: NCT01835249

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard BP arm
Description: Participants in the Standard BP arm have a goal of SBP \<140 mmHg.
Study: NCT03900533

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adjunctive group emotion regulation skills training
Description: The adjunctive emotion regulation skills training is delivered in a group format once a week during 7 weeks to adolescents and parents jointly together with treatment as usual

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Treatment as usual at the child- and adolescent psychiatric clinic is delivered during 7 weeks
Study: NCT01895751

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Invasive management
Description: Invasive management includes coronary and graft angiography (diagnostic imaging test) and coronary and/or graft revascularization with percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG), as clinically appropriate.
Study: NCT01333488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arctic Sun
Description: Core Body Temperature will be lowered using an Arctic Sun device to 34C. Bladder probe will monitor core temperature.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arctic Sun
Description: Core Body Temperature will be lowered using an Arctic Sun device to 34C. Bladder probe will monitor core temperature.
Study: NCT01042379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Paclitaxel + Encequidar + Dostarlimab (TSR-042) with or without trastuzumab
Description: For HER2+ Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Trastuzumab, 4 mg/kg cycle 1, then 2 mg/kg cycles 2-12 q1wk, IV, for wk1-12 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle~For HER2- Dostarlimab (TSR-042), 500 mg, IV, q3wks for wk 1, 4, 7, 10 Oral paclitaxel, 205 mg/m2, oral, daily for Three (3) days in a row each week for weeks 1-12 Oral encequidar, 15 mg, oral, daily for Three (3) days in a row each week for weeks 1-12 Followed by Doxorubicin: 60 mg/m2, IV, every 2 or 3 weeks for 4 cycles Cyclophosphamide: 600 mg/m2, IV, every 2 or 3 weeks for 4 cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amcenestrant
Description: Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amcenestrant + Abemaciclib
Description: Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Abemaciclib (Verzenio), 150mg BID, p.o., for 24 weeks
Study: NCT01333488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: IVI drug levels of Magnesium Sulfate targeted to plasma levels of magnesium of 2.5-3.5 mEq/Liter.(1.25-1.75mmol/L; or 3.04 - 4.26mg/dL)for 72 hours.
Study: NCT04522024

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epicardial focal cryoablation
Description: Epicardial focal cryoablation on the left atrium around right upper pulmonary vein area

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mei Mini Maze procedure
Description: Unilateral thoracoscopic epicardial ablation by radiofrequency energy from left side
Study: NCT03128879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Given BID
Study: NCT02915029

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational and lifestyle coaching
Description: Educational lifestyle and patient activation is a CHR lead home visits every other week to provide education on healthy lifestyles (diet, exercise, alcohol abuse and smoking) as patient preference; Education provided on management of diabetes, hypertension and hyperlipidemia POC testing for A1C and microalbuminuria conducted at patient homes. Lifestyle and diet related Motivational messaging carried out regularly. Patient will receive group session at the clinic every quarters.~Control arm will receive their usual care provided by IHS. The control group will receive a health evaluation at the initiation of the study and at the 6-month and 12-month.
Study: NCT00754182

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Octylcyanoacrylate (Dermabond)
Description: Synthetic glue for surgical use (skin closure)
Study: NCT01042379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amcenestrant + Letrozole
Description: Amcenestrant (SAR439859), 200mg QD, p.o., for 24 weeks Letrozole (Femara), 2.5mg QD, p.o., for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARX788
Description: ARX788, 1.5 mg/kg Q3W, IV for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARX788 + Cemiplimab
Description: ARX788, 1.5 mg/kg Q3W, IV for 12 weeks Cemiplimab, 350 mg Q3W, IV for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VV1 + Cemiplimab
Description: VV1, 3x10\^9 TCID50 once (day-8), Intra-tumoral injection Cemiplimab, 350 mg Q3W, IV for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan
Description: Dato-DXd, 6 mg/kg Q3W, IV for 12 weeks
Study: NCT00754182

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Subcuticular reabsorbable suture (Caprosyn)
Description: Every stitch is positioned in the subcuticular tissue by a continuous technique
Study: NCT02993679

Intervention type: PROCEDURE
Group type: OTHER
Intervention: reconstruction of the ACL and anterolateral ligament
Description: reconstruction of the ACL and anterolateral ligament

Intervention type: PROCEDURE
Group type: OTHER
Intervention: reconstruction of the ACL and anterolateral ligament
Description: reconstruction of the ACL and anterolateral ligament
Study: NCT03376178

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine and ropivacaine injection through catheters
Description: injection of local anesthetic through an endhole or a sixhole femoral nerve catheter in the context of total knee replacement. Analgesic properties at 24 and 48h of both groups registered.
Study: NCT01042379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Datopotamab deruxtecan + Durvalumab
Description: Dato-DXd, 6 mg/kg Q3W, IV for 12 weeks Durvalumab, 1120 mg Q3W, IV for 12 weeks
Study: NCT03376178

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: lidocaine and ropivacaine injection through catheters
Description: injection of local anesthetic through an endhole or a sixhole femoral nerve catheter in the context of total knee replacement. Analgesic properties at 24 and 48h of both groups registered.
Study: NCT01042379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanidatamab
Description: Zanidatamab: Flat dose of 1,200mg Q2W for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasofoxifene
Description: Lasofoxifene: 5.0 mg QD, p.o., for 24 weeks
Study: NCT04107571

Intervention type: PROCEDURE
Intervention: A type of operation for coranary heart disease patients.
Description: A type of operation for coranary heart disease patients.
Study: NCT01042379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-endoxifen
Description: Z-endoxifen: 10 mg QD, p.o., for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV-471
Description: ARV-471: 200 mg QD, p.o, for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV-471 + Letrozole
Description: ARV-471: 200 mg QD, p.o, for 24 weeks Letrozole: 2.5 mg QD, p.o, for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ARV-471 + Abemaciclib
Description: ARV-471: 200 mg QD, p.o, for 24 weeks Abemaciclib: 150 mg BID, p.o, for 24 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endoxifen + Abemaciclib
Description: Z-endoxifen: 80 mg QD, p.o., for 24 weeks Abemaciclib: 150 mg BID, p.o, for 20 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rilvegostomig + TDXd
Description: Rilvegostomig: 750mg IV Q3W for 12 weeks TDXd: 5.4 mg/kg IV Q3W for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dan222 + Niraparib
Description: DAN222: 8mg/m2 IV QW for 12 weeks Niraparib: 200mg QD p.p., 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab + Cemiplimab + Paclitaxel
Description: Sarilumab: 200mg Subcutaneous injection Q2W for 12 weeks Cemiplimab: 350mg IV Q3W for 12 weeks Paclitaxel: 80 mg/m2 IV QW for 12 weeks
Study: NCT02306967

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: resection of oral cancer
Description: Oral cancer will be resected.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: resection of oral cancer
Description: Oral cancer will be resected.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: resection of oral cancer
Description: Oral cancer will be resected

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: resection of oral cancer
Description: Oral cancer will be resected
Study: NCT01984138

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ESTRING
Description: ESTRING (estradiol vaginal ring) is a slightly opaque ring with a whitish core containing a drug reservoir of 2 mg estradiol. Estradiol, silicone polymers and barium sulfate are combined to form the ring. When placed in the vagina, ESTRING releases estradiol, approximately 7.5 mcg per 24 hours, in a consistent stable manner over 90 days. ESTRING has the following dimensions: outer diameter 55 mm; cross-sectional diameter 9 mm; core diameter 2 mm. One ESTRING should be inserted into the upper third of the vaginal vault, to be worn continuously for three months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Replens
Description: Replens should be applied vaginally, with a supplied applicator, three times each week.
Study: NCT02872922

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity therapeutic ultrasound
Description: The ultrasound equipment (Sonopulse III, 1 MHz, IBRAMED, Brazil) was calibrated with the radiation force method. In study, the head of the transducer will be positioned and applied for 5 min over the brachial artery at the same point that will be evaluated the endothelium function (Cruz et al., 2016). Continuous waveforms of ultrasound therapy (CWUT) are applied in the stationary mode for 5 minutes at a spatial averaged temporal intensity (SATA) of 0.4 W/cm2 using a transducer 1-MHz. A pulsed waveform of ultrasound therapy (PWUT) are applied (5 minutes) with a 20% duty cycle (2 ms on, 8 ms off), which represents a constant intensity of 0.08 W/cm2 SATA. In the placebo intervention, all of the procedures above are repeated, but with the ultrasound equipment powered off (Cruz et al., 2016).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity therapeutic ultrasound
Description: The ultrasound equipment (Sonopulse III, 1 MHz, IBRAMED, Brazil) was calibrated with the radiation force method. In study, the head of the transducer will be positioned and applied for 5 min over the brachial artery at the same point that will be evaluated the endothelium function (Cruz et al., 2016). Continuous waveforms of ultrasound therapy (CWUT) are applied in the stationary mode for 5 minutes at a spatial averaged temporal intensity (SATA) of 0.4 W/cm2 using a transducer 1-MHz. A pulsed waveform of ultrasound therapy (PWUT) are applied (5 minutes) with a 20% duty cycle (2 ms on, 8 ms off), which represents a constant intensity of 0.08 W/cm2 SATA. In the placebo intervention, all of the procedures above are repeated, but with the ultrasound equipment powered off (Cruz et al., 2016).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity therapeutic ultrasound
Description: The ultrasound equipment (Sonopulse III, 1 MHz, IBRAMED, Brazil) was calibrated with the radiation force method. In study, the head of the transducer will be positioned and applied for 5 min over the brachial artery at the same point that will be evaluated the endothelium function (Cruz et al., 2016). Continuous waveforms of ultrasound therapy (CWUT) are applied in the stationary mode for 5 minutes at a spatial averaged temporal intensity (SATA) of 0.4 W/cm2 using a transducer 1-MHz. A pulsed waveform of ultrasound therapy (PWUT) are applied (5 minutes) with a 20% duty cycle (2 ms on, 8 ms off), which represents a constant intensity of 0.08 W/cm2 SATA. In the placebo intervention, all of the procedures above are repeated, but with the ultrasound equipment powered off (Cruz et al., 2016).
Study: NCT04409028

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronal restoration
Description: A restorative material like composite resin is condensed into the cavity of teeth.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronal restoration
Description: A restorative material like composite resin is condensed into the cavity of teeth.
Study: NCT02748577

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Before the experimental session, participants will use REDCap to complete several questionnaires used to assess outcomes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Before the experimental session, participants will use REDCap to complete several questionnaires used to assess outcomes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quantitative Sensory Testing (QST) Pain Measurements
Description: Investigators will administer noxious thermal stimulation to assess pain threshold temperatures and assess responses to pain on measures of pain intensity and pain unpleasantness

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quantitative Sensory Testing (QST) Pain Measurements
Description: Investigators will administer noxious thermal stimulation to assess pain threshold temperatures and assess responses to pain on measures of pain intensity and pain unpleasantness
Study: NCT02009033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer
Description: When normovolæmic status of the patient is secured, 35 ml/kg of the allocated fluid is infused during the operation (estimated time for this type of operation is 180 minutes), however max. 3500 ml.Lactated Ringer is the interventional medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyethylstarch
Study: NCT04088682

Intervention type: BEHAVIORAL
Intervention: Quality improvement strategies and tools
Description: Quality improvement strategies and tools
Study: NCT02645916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danggui-Sayuk-Ga-Osuyu-Saenggang-tang
Description: Usage: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: corn starch
Description: Usage: 3g three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM \& FOODS Co. Ltd.
Study: NCT01996969

Intervention type: DRUG
Group type: OTHER
Intervention: Regorafenib
Description: Regorafenib will be given 160mg once daily for 3 weeks, followed by a 1 week rest. Treatment will be continued until disease progression or unacceptable toxicity occurs. Response evaluation (CT scans) will be performed every 2 cycles.
Study: NCT01546116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADEFOVIR, LAMIVUDINE
Description: Adefovir/10mg tablet/once a day/52week Lamivudine/100mg tablet/once a day/52week
Study: NCT00414661

Intervention type: DRUG
Intervention: CP-690,550
Description: Subjects had to have received CP-690,550 or other blinded study drug in index study. No intervention in this long-term follow-up trial.
Study: NCT06650345

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supervised aerobic exercise
Description: In this training program, the participants exercised for 45-60 minutes through intervals on a treadmill, bike, or stair climber, three times a week for 12 weeks.
Study: NCT01197469

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Tadalafil 10mg once daily for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03710278

Intervention type: DEVICE
Intervention: LPat Device
Description: Performing Lumbar Puncture utilizing LPat device
Study: NCT03031288

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A
Description: standard bottle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: A
Description: standard bottle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B
Description: vented base bottle

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: B
Description: vented base bottle
Study: NCT04126928

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Screening using DMFT and PUFA, orthopantomogram is taken and assessed using PAI, comprehensive clinical examination to diagnose pulpal and periapical conditions.
Study: NCT03235024

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: B244
Description: B244 suspension

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle suspension
Study: NCT00357370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, once daily, up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, once daily, up to 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, once daily, up to 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, once daily, up to 12 weeks
Study: NCT03775668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 µCi of 14C-AAI101 + 500 mg AAI101
Description: Single dose open label
Study: NCT06469255

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet Treatment
Description: 4 weeks low calorie diet treatment
Study: NCT02432716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Description: Insulin (glulisine) Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril), once per study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin glulisine
Description: Insulin (glulisine) Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril), once per study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Placebo Comparator: Placebo Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril), once per study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saline
Description: Placebo Comparator: Placebo Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril), once per study
Study: NCT02100891

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic HCT
Description: Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donor NK Cell Infusion
Description: Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
Study: NCT01790464

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% Lidocaine
Description: 2% lidocaine and peritonsillar instillation of gauze soaked with 2% lidocaine (Glossopharyngeal Group).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo